Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$82.2 million.

  • Kymera Therapeutics' Net Income towards Common Stockholders fell 3150.74% to -$82.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.1 million, marking a year-over-year decrease of 7621.96%. This contributed to the annual value of -$223.9 million for FY2024, which is 5232.37% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Net Income towards Common Stockholders is -$82.2 million, which was down 3150.74% from -$76.6 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Net Income towards Common Stockholders registered a high of -$13.1 million during Q1 2021, and its lowest value of -$82.2 million during Q3 2025.
  • Its 5-year average for Net Income towards Common Stockholders is -$44.8 million, with a median of -$40.9 million in 2023.
  • In the last 5 years, Kymera Therapeutics' Net Income towards Common Stockholders soared by 5878.96% in 2023 and then crashed by 39242.76% in 2024.
  • Kymera Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$34.0 million in 2021, then fell by 2.41% to -$34.9 million in 2022, then skyrocketed by 58.79% to -$14.4 million in 2023, then crashed by 392.43% to -$70.8 million in 2024, then dropped by 16.15% to -$82.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$82.2 million for Q3 2025, versus -$76.6 million for Q2 2025 and -$65.6 million for Q1 2025.